I have been thinking about Black Friday and holiday
I have been thinking about Black Friday and holiday wishes… I know what I want and if things work out we should be able to attain the beginnings of my wish this coming year. If you’re listening Santa here is what I want…
The 200 million shares opens the possibilities of not only securing our financing of our trials and purchase of Leronlimab from Samsung. If the next few catalysts do what we hope they do in securing a accent to a much higher stock price. Then the possibilities run rampant with my wish. More stock price value gives us independence to grow our company quickly with larger purchases of Leronlimab. To give us that jolt of not having to wait for the revenue to come before we repurchase again and again. Once revenue starts making a large purchase is priority to kick starting this company in the right direction. Having the funds to do it before waiting 90 days for revenue to show as companies usually pay within that time period. Could be a real slow down. It’s a big opportunity to be able to finance a quicker purchase and grow grow grow…
If you’re wondering what my wish is and you know from my past posts. It will be no surprise. My wish is we become our own pharmaceutical company and grow grow grow. This coming year is our year for a few approvals and after two approvals my dream becomes true I believe. Give us two approvals in Cancer and a few Covid indications and throw in a late BLA approval in HIV and my dream of my wish very much becomes true. Why is that you say? Because after a couple of quick approvals this year… nobody will be able to afford to buy us out. We will grow into our own big Pharma and grow into a top 10 in the world if not top 3 on so many Block Buster Indications we have defined. We don’t need any partners in any indication either. Let me say that again… we don’t need any partners!!!
This coming year is so exciting and yet we wait patiently as we have for the past few years. The difference is… we know trial results that are not just good but very good. This is a huge difference in waiting for a BLA and knowing we met the primary end point but just can’t get the handle on filing the BLA. A much approved position to be in.
We have taken the science of Leronlimab to new levels with better defined trials that have shown us proven results in Cancer mTNBC, Nash, HIV, Covid and even solid tumor cancers. Maybe even all cancers as we become an oncology company. We have many more autoimmune indications to look forward to also.
Our recent trials results can’t be denied and now just need to be explored a tiny bit more before we are well on our way. We hope this year produces BTD’s and BLA’s and a few quick EUA’s. Every indication trialed has been fast tracked process approved or will be including the Covid EUA temporary approval processes.
If you haven’t paid attention to the possibilities of what fast tracked means or says about our molecule… it say to me that the FDA recognizes the importance of the results of the molecule and wants to help us get there in approving it for each faster process we apply for. Ground breaking recognition. The 13d and shorts don’t want you to believe we have a good relationship with the FDA but if we did not have a good relationship… would we get all these faster processing approval processes? I don’t think so. So now is the time to believe in what we have and our future in my opinion.
If I am right then not only does my dream become true but we all become very well off with this investment. I believe by years end of 2022 we approach $100/share. That is just the beginning and I believe in a four figure stock price some day and that could be 5 years or maybe a tiny bit longer… but sooner than later when you do the math on each market indication as we seek Block Buster drug approvals on a true platform drug potential.
I know I am thankful to be invested in this miracle molecule. Recognizing the opportunities is just the start of knowing where we are headed. The future is so bright… we all have something to be thankful for this fine holiday.
Happy Holidays to you and yours and a very Happy Thanksgiving. Dream a little… dream of summer houses and boats and RV’s and international travel… this is what I dream about. Yes I am a true optimist and have optimistic opinions of Leronlimab. Live a little and and enjoy the possibilities we have before us… just dream a little!
13
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
FOX News Outshines Rivals in Midterm Coverage Diving into the chaos of the 2026 midterm elections, it’s clear FOX News Media’s strategic playbook outmaneuvered its cable competitors, chalking up a dominant ratings victory. Nielsen's final count places FOX News Channel (FNC) in the spotlight, their primetime broadcast drawing nearly 4.7 million viewers. And while some...
Continue Reading
Fresh Faces Navigate a Storied Institution In this unpredictable dance of leadership, the Boston Society of Architects (BSA) just laid its cards on the table for 2027. The latest board of directors and governance committees were announced with the kind of precision that shows how serious these folks are about preparing for a future that's anything but predictable. Handing...
Continue Reading
A Consistent Top Performer in the Cosmetic Surgery World When the same name pops up as the best in their field year after year, it's not just luck—it's a testament to their skills and dedication. Newsweek has ranked Dr. Rod J. Rohrich as the top facelift surgeon in the U.S. for six consecutive years. Now that’s one heck of a streak in the cutthroat world of cosmetic...
Continue Reading
Proposition 134: Leveling the Playing Field Here we go again, folks, another state digs in its heels on the issue of fairness in sports. This time, it's Colorado stepping into the spotlight, tipping the scales with Proposition 134. It's a move that keeps girls' sports strictly for girls, leaving no room for ambiguity when it comes to team designations. More than 1.25...
Continue Reading
Fresh Faces, New Dynamics: Navigating the 120th Congress Wake up and smell the Capitol Hill grind, folks. We've got the 120th Congress on our hands, brimming with fresh faces and a colossal shift in the political landscape. Thanks to our pals at Marathon Strategies, we've been thrown a bone with 'Meet The Freshmen'—a nonpartisan rundown of the latest political...
Continue Reading
David Coleman: Vaudit's New Ad Chief David Coleman stepping into Vaudit's spotlight as President of Advertising Industry is a twist worth watching. Vaudit, for those not up to speed, is an AI-driven powerhouse that keeps vendors in line with what they're charging. And let me tell you, Coleman's kind of heavy-hitter leadership doesn't come cheap, nor does it play nice with...
Continue Reading
A Dynamic Shift in Thrift Shopping All eyes might be on Thryfter this November as they drop some serious retail knowledge at the Goodwill CONNECT Conference in Houston. We’re talking about a tech shake-up for Goodwill’s model, thanks to Thryfter's livestream shopping craze that’s poised to weld traditional thrifting with digital reach. The Power of Virtual Thrift...
Continue Reading
A Leap Toward Future Growth You know, not every day does a company manage to turn its early beginnings into a robust franchise system, but Dill Dinkers seems to be onto something here. This pickleball outfit is tossing its original Maryland clubs to local hands, and it’s not just a transaction—it’s a calculated play intending to solidify their expansion path...
Continue Reading
Sasken's Bold Step Into Automotive Future Ah, nothing quite like the automotive industry trying to catch up with the tech world. That's where Sasken Technologies Ltd. stands, hand in hand with a major European automaker, rolling out the next phase of telematics control units (TCUs). This endeavor is a multi-year gig, not your fly-by-night partnership, mind you. It's all...
Continue Reading
The Unsung Heroes of the Mango Aisle You ever look around a grocery store and wonder who's behind those flashy displays that make a mango seem like the most appealing fruit in the aisle? Well, this year, four retailers got their pat on the back from the National Mango Board for doing just that—H-E-B, Rouses, Nugget Market, and Superior Grocers. Let me tell you, these...
Continue Reading
Top 5 Most Recently Viewed Articles
Understanding Hachiko: A Unique Dog Memecoin In the fast-paced world of cryptocurrency, where countless tokens emerge daily, Hachiko has carved a niche for itself, symbolizing loyalty and strength. Inspired by the true story of a devoted dog, Hachiko offers not just a meme coin but a movement rooted in shared values and community spirit. As more crypto enthusiasts are...
Continue Reading
Understanding Netcompany's Share Buyback Program Recently, Netcompany Group A/S initiated an engaging share buyback program aimed at up to DKK 500 million and up to 3,700,000 shares. This strategic decision is part of their effort to realign their capital structure while also addressing obligations related to share-based incentive programs. Program Execution and...
Continue Reading
Silo Pharma's Strategic Investment in Decentralized Science Silo Pharma, Inc. (Nasdaq: SILO), known for its diverse portfolio in biopharmaceuticals and cryptocurrency holdings, has taken a significant step by investing in ResearchCoin (RSC). This move signals the company's commitment to harnessing decentralized innovations that could reshape the scientific research...
Continue Reading
Shake-Up in Academic Publishing Something's brewing in the academic publishing world—Elsevier and Jisc just inked a three-year deal. This ain't your run-of-the-mill handshake; it's a read-and-publish agreement for UK institutions. That's huge, right? This agreement lets UK schools keep reading Elsevier's well-respected journals while giving selected authors a chance to...
Continue Reading
Ambow Education Shares Show Mixed Signals Ambow Education Holding Ltd. (AMBO) has seen some interesting developments in its share prices recently. After a remarkable surge in share price, the company’s stock is experiencing a downward trend in premarket trading. Investors are reacting to the dynamics of the market as well as strategic moves made by the company. Key...
Continue Reading